Designation of Factor XI Concentrate (Human Coagulation Factor XI) as an Orphan Drug - CSL Behring (Australia) Pty Ltd

Administered by Department of Health, Disability and Ageing

Legislation au C2015G00022 In force Gazette

Legislation content

COMMONWEALTH OF AUSTRALIA

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

 

DESIGNATION OF Factor XI Concentrate (human coagulation factor XI) AS AN ORPHAN DRUG

 

I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 (“the Regulations”), acting under subregulation 16J(2) of the Regulations, designate Factor XI Concentrate (human coagulation factor XI) as an orphan drug on 31 October 2014 for the treatment and prevention of bleeding in patients with either congenital factor XI deficiency or acquired factor XI inhibitors.

The dose form of Factor XI Concentrate (human coagulation factor XI) for this indication is powder for injection.

The sponsor of Factor XI Concentrate (human coagulation factor XI) is CSL Behring (Australia) Pty Ltd.

 

(Signed by)

 

Dr Anthony Gill

Delegate of the Secretary

12 December 2014

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.